Annual revenue:
$2.25B+$419.95M(+22.97%)Summary
- As of today (April 19, 2025), ALNY annual revenue is $2.25 billion, with the most recent change of +$419.95 million (+22.97%) on December 31, 2024.
- During the last 3 years, ALNY annual revenue has risen by +$1.40 billion (+166.29%).
- ALNY annual revenue is now at all-time high.
Performance
ALNY Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly revenue:
$593.17M+$92.25M(+18.42%)Summary
- As of today (April 19, 2025), ALNY quarterly revenue is $593.17 million, with the most recent change of +$92.25 million (+18.42%) on December 31, 2024.
- Over the past year, ALNY quarterly revenue has increased by +$153.45 million (+34.90%).
- ALNY quarterly revenue is now -20.97% below its all-time high of $750.53 million, reached on September 30, 2023.
Performance
ALNY Quarterly revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM revenue:
$2.25B+$153.45M(+7.33%)Summary
- As of today (April 19, 2025), ALNY TTM revenue is $2.25 billion, with the most recent change of +$153.45 million (+7.33%) on December 31, 2024.
- Over the past year, ALNY TTM revenue has increased by +$419.95 million (+22.97%).
- ALNY TTM revenue is now -4.10% below its all-time high of $2.34 billion, reached on June 30, 2024.
Performance
ALNY TTM revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
ALNY Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.0% | +34.9% | +23.0% |
| 3 y3 years | +166.3% | +34.9% | +23.0% |
| 5 y5 years | +923.1% | +34.9% | +23.0% |
ALNY Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +166.3% | -21.0% | +178.1% | -4.1% | +155.5% |
| 5 y | 5-year | at high | +923.1% | -21.0% | +496.3% | -4.1% | +686.3% |
| alltime | all time | at high | >+9999.0% | -21.0% | >+9999.0% | -4.1% | >+9999.0% |
Alnylam Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $2.25B(+23.0%) | $593.17M(+18.4%) | $2.25B(+7.3%) |
| Sep 2024 | - | $500.92M(-24.1%) | $2.09B(-10.6%) |
| Jun 2024 | - | $659.83M(+33.5%) | $2.34B(+17.0%) |
| Mar 2024 | - | $494.33M(+12.4%) | $2.00B(+9.6%) |
| Dec 2023 | $1.83B(+76.2%) | $439.72M(-41.4%) | $1.83B(+6.1%) |
| Sep 2023 | - | $750.53M(+135.5%) | $1.72B(+39.3%) |
| Jun 2023 | - | $318.75M(-0.2%) | $1.24B(+8.2%) |
| Mar 2023 | - | $319.29M(-4.7%) | $1.14B(+10.2%) |
| Dec 2022 | $1.04B(+22.9%) | $335.04M(+26.8%) | $1.04B(+8.0%) |
| Sep 2022 | - | $264.31M(+17.6%) | $960.92M(+8.7%) |
| Jun 2022 | - | $224.82M(+5.4%) | $884.25M(+0.5%) |
| Mar 2022 | - | $213.26M(-17.5%) | $879.98M(+4.2%) |
| Dec 2021 | $844.29M(+71.3%) | $258.54M(+37.8%) | $844.29M(+12.7%) |
| Sep 2021 | - | $187.63M(-14.9%) | $749.31M(+9.0%) |
| Jun 2021 | - | $220.55M(+24.2%) | $687.53M(+20.4%) |
| Mar 2021 | - | $177.57M(+8.6%) | $570.94M(+15.8%) |
| Dec 2020 | $492.85M(+124.3%) | $163.56M(+30.0%) | $492.85M(+22.9%) |
| Sep 2020 | - | $125.85M(+21.1%) | $400.97M(+16.2%) |
| Jun 2020 | - | $103.96M(+4.5%) | $345.18M(+20.7%) |
| Mar 2020 | - | $99.48M(+38.8%) | $285.93M(+30.1%) |
| Dec 2019 | $219.75M(+193.4%) | $71.68M(+2.3%) | $219.75M(+30.0%) |
| Sep 2019 | - | $70.06M(+56.7%) | $169.10M(+67.2%) |
| Jun 2019 | - | $44.71M(+34.3%) | $101.11M(+17.2%) |
| Mar 2019 | - | $33.29M(+58.3%) | $86.30M(+15.2%) |
| Dec 2018 | $74.91M(-16.7%) | $21.03M(+916.6%) | $74.91M(-18.4%) |
| Sep 2018 | - | $2.07M(-93.1%) | $91.80M(-14.1%) |
| Jun 2018 | - | $29.91M(+36.6%) | $106.83M(+15.1%) |
| Mar 2018 | - | $21.90M(-42.3%) | $92.85M(+3.3%) |
| Dec 2017 | $89.91M(+90.7%) | $37.92M(+121.8%) | $89.91M(+29.5%) |
| Sep 2017 | - | $17.10M(+7.3%) | $69.44M(+5.2%) |
| Jun 2017 | - | $15.93M(-16.0%) | $66.00M(+12.3%) |
| Mar 2017 | - | $18.96M(+8.6%) | $58.77M(+24.6%) |
| Dec 2016 | $47.16M(+14.8%) | $17.45M(+27.9%) | $47.16M(+26.6%) |
| Sep 2016 | - | $13.65M(+56.7%) | $37.26M(+24.5%) |
| Jun 2016 | - | $8.71M(+18.6%) | $29.93M(+0.1%) |
| Mar 2016 | - | $7.34M(-2.7%) | $29.91M(-27.2%) |
| Dec 2015 | $41.10M(-18.7%) | $7.55M(+19.4%) | $41.10M(-28.6%) |
| Sep 2015 | - | $6.32M(-27.2%) | $57.56M(-7.5%) |
| Jun 2015 | - | $8.69M(-53.1%) | $62.21M(+2.3%) |
| Mar 2015 | - | $18.54M(-22.8%) | $60.82M(+20.3%) |
| Dec 2014 | $50.56M | $24.02M(+118.9%) | $50.56M(+35.2%) |
| Sep 2014 | - | $10.97M(+50.4%) | $37.39M(+5.6%) |
| Jun 2014 | - | $7.29M(-11.8%) | $35.41M(-3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $8.28M(-23.7%) | $36.80M(-22.0%) |
| Dec 2013 | $47.17M(-29.3%) | $10.85M(+20.6%) | $47.17M(+5.2%) |
| Sep 2013 | - | $8.99M(+3.5%) | $44.81M(-14.8%) |
| Jun 2013 | - | $8.69M(-53.4%) | $52.58M(-18.8%) |
| Mar 2013 | - | $18.64M(+119.4%) | $64.78M(-2.9%) |
| Dec 2012 | $66.72M(-19.4%) | $8.49M(-49.3%) | $66.72M(-15.2%) |
| Sep 2012 | - | $16.76M(-19.8%) | $78.69M(-4.9%) |
| Jun 2012 | - | $20.88M(+1.4%) | $82.72M(+0.3%) |
| Mar 2012 | - | $20.59M(+0.6%) | $82.45M(-0.4%) |
| Dec 2011 | $82.76M(-17.3%) | $20.45M(-1.6%) | $82.76M(-0.9%) |
| Sep 2011 | - | $20.79M(+0.9%) | $83.49M(-7.6%) |
| Jun 2011 | - | $20.61M(-1.4%) | $90.37M(-6.2%) |
| Mar 2011 | - | $20.90M(-1.4%) | $96.37M(-3.7%) |
| Dec 2010 | $100.04M(-0.5%) | $21.19M(-23.4%) | $100.04M(-5.2%) |
| Sep 2010 | - | $27.67M(+3.9%) | $105.47M(+3.4%) |
| Jun 2010 | - | $26.62M(+8.4%) | $102.06M(+2.0%) |
| Mar 2010 | - | $24.56M(-7.7%) | $100.04M(-0.5%) |
| Dec 2009 | $100.53M(+4.5%) | $26.63M(+9.8%) | $100.53M(+2.3%) |
| Sep 2009 | - | $24.25M(-1.4%) | $98.31M(-1.5%) |
| Jun 2009 | - | $24.60M(-1.8%) | $99.80M(+0.8%) |
| Mar 2009 | - | $25.06M(+2.7%) | $99.03M(+3.0%) |
| Dec 2008 | $96.16M(+88.9%) | $24.40M(-5.2%) | $96.16M(+6.9%) |
| Sep 2008 | - | $25.73M(+8.0%) | $89.99M(+11.7%) |
| Jun 2008 | - | $23.83M(+7.4%) | $80.57M(+22.3%) |
| Mar 2008 | - | $22.19M(+21.7%) | $65.87M(+29.4%) |
| Dec 2007 | $50.90M(+89.0%) | $18.23M(+11.7%) | $50.90M(+28.4%) |
| Sep 2007 | - | $16.32M(+78.6%) | $39.65M(+25.7%) |
| Jun 2007 | - | $9.13M(+26.5%) | $31.54M(+10.9%) |
| Mar 2007 | - | $7.22M(+3.4%) | $28.43M(+5.6%) |
| Dec 2006 | $26.93M(+371.1%) | $6.98M(-15.0%) | $26.93M(+25.2%) |
| Sep 2006 | - | $8.21M(+36.4%) | $21.50M(+46.2%) |
| Jun 2006 | - | $6.02M(+5.3%) | $14.70M(+50.2%) |
| Mar 2006 | - | $5.72M(+268.4%) | $9.79M(+71.3%) |
| Dec 2005 | $5.72M(+33.6%) | $1.55M(+9.8%) | $5.72M(-16.1%) |
| Sep 2005 | - | $1.41M(+27.5%) | $6.81M(+0.7%) |
| Jun 2005 | - | $1.11M(-32.6%) | $6.76M(+16.9%) |
| Mar 2005 | - | $1.64M(-37.9%) | $5.79M(+35.3%) |
| Dec 2004 | $4.28M(+2330.7%) | $2.65M(+93.6%) | $4.28M(+155.3%) |
| Sep 2004 | - | $1.37M(+943.5%) | $1.68M(+374.8%) |
| Jun 2004 | - | $131.00K(-2.2%) | $353.00K(+59.0%) |
| Mar 2004 | - | $134.00K(+204.5%) | $222.00K(+152.3%) |
| Dec 2003 | $176.00K | $44.00K(0.0%) | $88.00K(+100.0%) |
| Sep 2003 | - | $44.00K | $44.00K |
FAQ
- What is Alnylam Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual revenue year-on-year change?
- What is Alnylam Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?
- What is Alnylam Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM revenue year-on-year change?
What is Alnylam Pharmaceuticals annual revenue?
The current annual revenue of ALNY is $2.25B
What is the all time high annual revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual revenue is $2.25B
What is Alnylam Pharmaceuticals annual revenue year-on-year change?
Over the past year, ALNY annual revenue has changed by +$419.95M (+22.97%)
What is Alnylam Pharmaceuticals quarterly revenue?
The current quarterly revenue of ALNY is $593.17M
What is the all time high quarterly revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly revenue is $750.53M
What is Alnylam Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, ALNY quarterly revenue has changed by +$153.45M (+34.90%)
What is Alnylam Pharmaceuticals TTM revenue?
The current TTM revenue of ALNY is $2.25B
What is the all time high TTM revenue for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM revenue is $2.34B
What is Alnylam Pharmaceuticals TTM revenue year-on-year change?
Over the past year, ALNY TTM revenue has changed by +$419.95M (+22.97%)